Granisetron Lek (Granisetron)

Granisetron Lek is indicated for the prevention of nausea and vomiting in specific clinical situations.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) after surgical procedures.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Administration in settings where rapid onset of antiemetic effect is required, such as during infusion of cytotoxic agents.
• Intravenous dosing allows for controlled plasma concentrations during short‑term antiemetic therapy.
• May be used in combination with corticosteroids or NK‑1 antagonists to enhance anti‑nausea efficacy.

Granisetron Lek can cause a range of adverse effects, which are generally categorized as common or serious based on frequency and clinical significance.

Common

• Headache
• Constipation or mild abdominal discomfort
• Dizziness or light‑headedness
• Transient flushing or warmth sensation
• Dry mouth or mild taste alteration
• Transient visual disturbances such as blurred vision

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing
• Cardiac arrhythmias, including QT interval prolongation
• Persistent severe constipation leading to bowel obstruction
• Elevated liver enzymes indicating hepatic stress
• Seizure activity in patients with pre‑existing neurological disorders
• Hypotension or cardiovascular collapse in susceptible individuals
• Most patients tolerate the medication well, but monitoring is advised.

When prescribing Granisetron Lek, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Evaluate cardiac risk, especially in patients with known QT prolongation or electrolyte disturbances.
• Use caution in individuals with hepatic impairment; dose adjustment may be required.
• Monitor for signs of constipation, particularly in patients with gastrointestinal motility disorders.
• Consider potential interactions with other antiemetics or serotonergic agents.
• Review pregnancy and lactation status, as safety data are limited.

Granisetron Lek may interact with other medications, and certain combinations should be avoided or used with caution.

Avoid

• Concurrent use with other 5‑HT3 antagonists, as additive effects increase risk of cardiac arrhythmias.
• Combination with potent CYP3A4 inducers that may reduce granisetron plasma levels.
• Avoid simultaneous infusion with high-dose dexamethasone that may mask granisetron efficacy.

Use with caution

• Co‑administration with drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).
• Use alongside serotonergic agents such as SSRIs or tramadol, which may increase serotonin syndrome risk.
• Concomitant use with opioids that have emetogenic potential, requiring close monitoring.
• Caution when combined with other antiemetics that have overlapping mechanisms, such as metoclopramide, to prevent excessive serotonin blockade.